Evidence map›Paper›PMID 26034371›Full record

SynthesisWorld journal of gastroenterology2015

Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.

Yu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07495644 (Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt), which is not on this map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07495644 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt

TypeobservationalSponsorAssiut UniversityRan2026 to 2027Enrolled95ConditionsInflamatory Bowel Disease (Crohn&#39, s and Ulcerative Colitis)Armsadalimumab, infliximab, ustekinumab, golimumab, and vedolizumab
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Vedolizumab in Inflammatory Bowel Disease: West versus East.Inflammatory intestinal diseases · 2021
    Review
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu JinYu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China.
Yan LinYu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China.
Lian-Jie LinYu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China.
Chang-Qing ZhengYu Jin, Yan Lin, Lian-Jie Lin, Chang-Qing Zheng, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo conduct a meta-analysis examining the effectiveness and safety of vedolizumab for the treatment of ulcerative colitis (UC).

methodsA search was conducted of MEDLINE, Cochrane, EMBASE, and Google Scholar on July 31, 2013. Inclusion criteria were: (1) Randomized controlled trial (RCT); (2) Patients treated for UC; and (3) Intervention was vedolizumab. The following information/data were extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, patient demographic information, response rate, remission rate, and adverse events. The primary outcome was clinical response rate, and the secondary outcomes were clinical remission rate and serious adverse events. Odds ratio (OR) with 95%CI were calculated for each outcome.

resultsOf 224 studies initially identified, three RCTs examining the use of vedolizumab meeting the inclusion criteria were included in the meta-analysis. All studies examined the use of vedolizumab at dosages ranging from 0.5 to 10 mg/kg body weight (one study used a standard dose of 300 mg). The follow-up periods were approximately 6 wk. The total number of patients in the intervention groups was 901, and in the control groups was 221. The mean age of the patients was approximately 41 years, and approximately half were males. The follow-up periods ranged from 43 d to 6 wk. The clinical response and remission rates were significantly higher for patients who received vedolizumab as compared to control patients (clinical response: OR = 2.69; 95%CI: 1.94-3.74, P < 0.001 and remission rate: OR = 2.72; 95%CI: 1.76-4.19, P < 0.001). Serious adverse events were not higher in patients that received vedolizumab.

conclusionThis analysis supports the use of vedolizumab for the treatment of UC.

Indexed as

AdultAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsColitis, UlcerativeFemaleGastrointestinal AgentsHumansMaleOdds RatioRemission InductionRisk FactorsTime FactorsTreatment OutcomeAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsGastrointestinal AgentsvedolizumabInflammatory bowel diseaseMeta-analysisMLN-002Ulcerative colitisVedolizumab

Identifiers

PMID26034371
PMCPMC4445113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.